ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 0651 • ACR Convergence 2024

    Renal Survival and Mortality in Patients with Proliferative and Membranous Lupus Nephritis

    Jung-Min Shin1, Jiyoung Lee2, Hye-Soon Lee3, Sang-Cheol Bae3 and So-Young Bang3, 1Department of Rheumatology, Nowon Eulji Medical Center, Seoul, Republic of Korea, 2Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, 3Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

    Background/Purpose: Lupus nephritis (LN) affects approximately 50% of patients and is a major determinant in the survival and prognosis of patients with systemic lupus erythematosus…
  • Abstract Number: 0669 • ACR Convergence 2024

    Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study

    buddhika Jayaratna1, Pasan Serasinghe2, Louise Nel3, Sahil Jain3, Shrish Sangle2, Begona Lopez1, Giovanni Sanna2, Michelle Fernando1 and David DCruz4, 1Guys & St Thomas NHS Foundation Trust, London, United Kingdom, 2Guys & St Thomas NHS Foundation Trust, London, England, United Kingdom, 3Guys and St Thomas' Hospital, London, United Kingdom, 4The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
  • Abstract Number: 0843 • ACR Convergence 2024

    External Validation and Extension of Population-Based Systemic Lupus Erythematosus Risk Prediction Models Using Genetics, and Lifestyle and Environmental Factors

    Jacob J.E. Koopman1, Jing Cui1, Hongshu Guan1, Emma Stevens1, Emily Oakes1 and Karen Costenbader2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital/ Harvard Medical School, Boston, MA

    Background/Purpose: Many genetic and environmental risk factors for SLE are now known. We have developed SLE risk prediction models, incorporating known genetic, lifestyle, and environmental…
  • Abstract Number: 1037 • ACR Convergence 2024

    Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review

    Alice Terrett1, Athena Chin2, Mihye Kwon3, Samuel Whittle4 and Catherine Hill5, 1The Queen Elizabeth Hospital, Adelaide, Australia, 2Royal Adelaide Hospital, Tranmere, South Australia, Australia, 3Konyang University, College of Medicine, Daejeon, Republic of Korea, 4The Queen Elizabeth Hospital, Springfield, South Australia, Australia, 5The Queen Elizabeth Hospital, Woodville, South Australia, Australia

    Background/Purpose: The use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), has significantly improved disease and functional…
  • Abstract Number: 1257 • ACR Convergence 2024

    The Immune and Growth Characteristics of Children Born to Mothers with Systemic Lupus Erythematosus

    Wenqiong Wang1, Xiaodan Hu1, Haoxiang Wang1, Siyue Yu1, Meng Xie1, Shuming Shao1, chun Li1 and Jing He2, 1Peking University People's Hospital, Beijing, China, 2Rheumatology, Beijing, China

    Background/Purpose: The aim of this study was to assess the immune, growth and development characteristics in offspring born to mothers with systemic lupus erythematosus (SLE).Methods:…
  • Abstract Number: 1283 • ACR Convergence 2024

    Acute Transverse Myelitis in Pediatric Systemic Lupus Erythematosus

    Meredith Rae1, Emily Beil2, Juan Carlos Torres2, Kristen Fisher2 and Eyal Muscal3, 1Baylor College of Medicine/Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine/Texas Children's Hospital, Houston, 3Baylor College of Medicine, Houston, TX

    Background/Purpose: Transverse myelitis (TM) has an incidence of 1-2% in pediatric SLE and is often a feature of early disease. Most patients ( >60%) have…
  • Abstract Number: 1497 • ACR Convergence 2024

    Type I Interferon Status and Clinical Manifestations in a Large Cohort of Patients with Systemic Lupus Erythematosus

    Justin Smith1, Laura Patricia Whittall Garcia2, Dennisse Bonilla2, Qixuan Li2, Robert Terbrueggen3, Hemani Wijesuriya3, Ian Richards3, Aviva Jacobs3, Joan Wither2, Dafna Gladman4 and Zahi Touma5, and DxTerity, 1University of Toronto, Toronto, AB, Canada, 2University Health Network, Toronto, ON, Canada, 3DxTerity Diagnostics Inc., Torrance, CA, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada

    Background/Purpose: Type I interferons (IFN) are pivotal in the pathogenesis of SLE, with studies showing high IFN gene signature (IGS) status associated with certain organ…
  • Abstract Number: 1513 • ACR Convergence 2024

    Assessing Subjective Cognitive Impairment in a Cohort of Canadian Systemic Lupus Erythematosus Patients: Construct Validity of PDQ-20

    Omar Marzouk1, J. Antonio Avina-Zubieta2, Mary Fox3, William Shaw4, Maggie Ho5, Qixuan Li5, Catherine Ivory6, Paul Fortin7, Kathleen Bingham5, Stephanie Keeling8, Jennifer Reynolds9, Derek Haaland10, Janet Pope11, Lily Lim12, Patti Katz13, Murray Urowitz14, Laura Patricia Whittall Garcia5, Dafna Gladman15, Behdin Nowrouzi-Kia16 and Zahi Touma16, 1Toronto Western Hospital, Toronto, 2Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 3York University, Toronto, ON, Canada, 4University of Connecticut, School of Medicine, Farmington, CT, 5University Health Network, Toronto, ON, Canada, 6The Ottawa Hospital, Ottawa, ON, Canada, 7Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 8University of Alberta, Edmonton, AB, Canada, 9UBC, North Vancouver, BC, Canada, 10The Waterside Clinic, Oro Medonte, ON, Canada, 11University of Western Ontario, London, ON, Canada, 12University of Manitoba, Winnipeg, MB, Canada, 13UCSF, San Rafael, CA, 14Self employed, Toronto, ON, Canada, 15University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 16University of Toronto, Toronto, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) has many symptoms, including cognitive impairment (CI), which negatively impacts social role participation and quality of life. CI is highly…
  • Abstract Number: 1530 • ACR Convergence 2024

    Belimumab-Treated Patients with Systemic Lupus Erythematosus Without Prior Immunosuppressant Use Have More Favorable Clinical Outcomes Than Those with Prior Use of an Immunosuppressant

    Maral DerSarkissian1, Yan Chen1, Brendan Rabideau1, Theo Man1, Karen Worley2, Bernard Rubin3, Karen Costenbader4 and S. Sam Lim5, 1Analysis Group, Los Angeles, CA, 2GSK, Collegeville, PA, 3GSK, Durham, NC, 4Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 5Emory University, Atlanta, GA

    Background/Purpose: Early diagnosis and treatment of SLE improves prognosis and quality of life.1 Belimumab (BEL), a human immunoglobulin G1λ (IgG1λ) mAb that selectively binds to…
  • Abstract Number: 1550 • ACR Convergence 2024

    CD19 CAR T Cell Therapy Suppresses the Inflammatory Profile of Neutrophils in Systemic Lupus Erythematosus

    Panagiotis Garantziotis1, Kirill Anoshkin1, Melanie Hagen2, Andreas Wirsching2, Andreas MAckensen3, Georg Schett4 and Ricardo Grieshaber-Bouyer5, 1Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 3Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 5Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) exhibit increased formation of Neutrophil Extracellular Traps and production of proinflammatory cytokines, which can perpetuate autoimmunity. Furthermore, NETs…
  • Abstract Number: 1701 • ACR Convergence 2024

    STING Pathway Activity in SLE Patient Serum Correlates with NFkB Activation, Autoantibody Levels, and a Unique Cytokine Profile That Drives Disease Activity

    Hyun Hee Kim1, Haochen Jiang2, Tatiana Ort3, Gary Sims3 and Richard Hanna4, 1AstraZeneca, Gaithersburg, MD, 2University of Nebraska, Omaha, NE, 3Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 4AstraZeneca, Dickerson, MD

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous systemic autoimmune disease which is associated with innate immune activation, type I IFN, inflammasome and NFkB-related cytokines.…
  • Abstract Number: 1783 • ACR Convergence 2024

    Deciphering the Roles of Mitochondrial-Related Genes and Ferroptosis in Systemic Lupus Erythematosus: Integrated Analysis for Diagnostic Biomarker Identification and Therapeutic Insights

    Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Understanding the molecular mechanisms of SLE is crucial for developing effective…
  • Abstract Number: 1801 • ACR Convergence 2024

    Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus

    Tania Rowley1, Adnan R. Khan1, Laura McLaughlin1, Hannah Cherry1, Farnaz Fallah-Arani1, Yiannis Ioannou1, Debasish Pyne2 and Anthony Shock1, 1UCB Pharma, Slough, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…
  • Abstract Number: 1909 • ACR Convergence 2024

    Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study

    Insa Mannstadt1, Yiyuan Wu2 and Bella Mehta3, 1Columbia University VP&S, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: While systemic rheumatic diseases, including Sjogren's syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and spondyloarthropathies, are known to have severe ophthalmologic manifestations, there…
  • Abstract Number: 2184 • ACR Convergence 2024

    Loss to Follow up After Transfer from Pediatric to Adult Care in Patients with JIA or jSLE

    Simran Heera1, Matthew Sholdice2, Tania Cellucci3, Stephanie Garner4, Liane Heale5, Mark Matsos6, KAREN BEATTIE7 and Michelle Batthish3, 1McMaster University, Mississauga, ON, Canada, 2McMaster University, London, ON, Canada, 3McMaster Children's Hospital, Hamilton, ON, Canada, 4University of Calgary, Calgary, AB, Canada, 5McMaster University, Oakville, ON, Canada, 6McMaster Lupus Clinic, Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada, 7McMaster University, Hamilton, ON, Canada

    Background/Purpose: In Canada, adolescents with JIA and jSLE transfer from pediatric to adult care around age 18. This vulnerable transition period is associated with an…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology